Results 161 to 170 of about 204,272 (330)

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Comparative Risk Assessment in Hypertensive Patients With Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. [PDF]

Cureus
Khan MH, Pathan S, Ansari K, Baig S, Ghafoor A, Minhas M, Saleem K.   +6 more
europepmc   +1 more source

Hemodynamic Effects of Angiotensin-Converting Enzyme Inhibitors in Essential Hypertension

, 1985
M. A. Fitzpatrick, Stevo Julius
openalex   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. [PDF]

Healthcare (Basel)
Puigdellívol-Sánchez A, Juanes-González M, Calderón-Valdiviezo AI, Losa-Puig H, González-Salvador M, León-Pérez M, Pueyo-Antón L, Franco-Romero M, Lozano-Paz C, Cortés-Borra A, Valls-Foix R.   +10 more
europepmc   +1 more source

Antihypertensive Action of a Non-Sulfhydryl Angiotensin Converting Enzyme Inhibitor (CV-3317) in Various Hypertensive Models

, 1986
Yoshiyuki Inada, Masao J. Tanabe, Yumiko Shibouta, K Kawazoe, Kohei Nishikawa, Shintaro Kikuchi   +5 more
openalex   +1 more source

Enflurane, halothane and isoflurane do not inhibit angiotensin converting enzyme activity [PDF]

, 1985
James K. Alifimoff, Barbara W. Brandom, D. Ryan Cook   +2 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Whole Exome Sequencing in Drug-Induced Angioedema Caused by Angiotensin-Converting Enzyme Inhibitors: A Pilot Study in Five Patients. [PDF]

J Clin Med
Mendoza-Alvarez A, Martinez-Tadeo JA, Perez-Rodríguez E, Barrios-Recio J, García-Robaina JC, Corrales A, Marcelino-Rodríguez I, Lorenzo-Salazar JM, González-Montelongo R, Flores C, Callero A.   +10 more
europepmc   +1 more source

Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. [PDF]

World Allergy Organ J, 2023
Douillard M, Deheb Z, Bozon A, Raison-Peyron N, Dereure O, Moulis L, Soria A, Du-Thanh A.   +7 more
europepmc   +1 more source